By Ethan Covey
Less than half of liver transplant candidates given a new recombinant hepatitis B vaccine showed seroconversion following the vaccination series, according to data presented at IDWeek 2022, held in Washington, D.C. (poster 638).
The findings highlight the need for an improved strategy for hepatitis B vaccination among this patient population, the researchers said.
In 2017, the FDA approved a new recombinant, adjuvanted hepatitis B vaccine (HepB-CpG; Heplisav, Dynavax). During phase